NeuroBo Pharmaceuticals Inc (NRBO)
2.27
-0.12
(-5.02%)
USD |
NASDAQ |
Nov 15, 12:45
NeuroBo Pharmaceuticals Cash from Operations (Quarterly): -5.589M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -5.589M |
June 30, 2024 | -7.251M |
March 31, 2024 | -6.442M |
December 31, 2023 | -3.393M |
September 30, 2023 | -2.814M |
June 30, 2023 | -2.045M |
March 31, 2023 | -2.547M |
December 31, 2022 | -1.807M |
September 30, 2022 | -2.359M |
June 30, 2022 | -2.717M |
March 31, 2022 | -4.829M |
December 31, 2021 | -2.899M |
September 30, 2021 | -2.507M |
June 30, 2021 | -3.587M |
March 31, 2021 | -6.141M |
December 31, 2020 | -2.348M |
September 30, 2020 | -1.954M |
June 30, 2020 | -2.324M |
March 31, 2020 | -4.138M |
December 31, 2019 | -1.278M |
Date | Value |
---|---|
September 30, 2019 | -3.345M |
June 30, 2019 | -1.192M |
March 31, 2019 | -1.224M |
December 31, 2018 | 3.347M |
September 30, 2018 | -4.284M |
June 30, 2018 | -6.278M |
March 31, 2018 | -7.236M |
December 31, 2017 | -6.76M |
September 30, 2017 | -7.299M |
June 30, 2017 | -6.619M |
March 31, 2017 | -6.223M |
December 31, 2016 | -3.623M |
September 30, 2016 | -3.634M |
June 30, 2016 | -1.73M |
March 31, 2016 | -2.056M |
December 31, 2015 | -2.256M |
September 30, 2015 | -1.562M |
June 30, 2015 | -0.995M |
March 31, 2015 | -0.62M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-7.251M
Minimum
Jun 2024
-1.278M
Maximum
Dec 2019
-3.448M
Average
-2.766M
Median
Cash from Operations (Quarterly) Benchmarks
Cytokinetics Inc | -101.50M |
Ocugen Inc | -9.911M |
enVVeno Medical Corp | -4.276M |
Scholar Rock Holding Corp | -49.20M |
Mirum Pharmaceuticals Inc | -3.803M |
Cash from Operations (Quarterly) Related Metrics
Cash from Financing (Quarterly) | -0.676M |
Free Cash Flow | -22.69M |
Free Cash Flow Per Share (Quarterly) | -0.5472 |
Free Cash Flow Yield | -154.8% |